15.6% reported weight loss · 2.2% loss with placebo · 48 weeks
2.4 mg once weekly
Adults with obesity or overweight and comorbidity without diabetes
Reported mean weight change; exact intercurrent-event strategy not specified in the retrieved primary conference abstract. Investigational; obesity phase 2 results; MASH program separately advanced
Safety context
Mostly mild/moderate GI events; drug-related study discontinuation 15.5% at 2.4 mg.
Limitations: Conference abstract/sponsor evidence, not a full peer-reviewed paper; MASH-selected trials not mixed into this obesity result.
Investigational; no approved trade name identified as of 2026-09-13. Pemvidutide (ALT-801) has obesity evidence and separate liver-disease programs; its MASH designation is not an obesity approval.
Altimmune · Current developer; obtained pemvidutide through its acquisition of Spitfire Pharma.; Spitfire Pharma · Original development company acquired by Altimmune in July 2019.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates GLP-1 and glucagon receptors.
Structure not yet verified
Structure not verified
Activates GLP-1 and glucagon receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history4 selected milestones
Pemvidutide · compound history across indications
Selected dated milestones, not a complete development history. October 3 adds the recovered August 3 PERFORMA MASH enrollment announcement; the MOMENTUM obesity results and their original dates are unchanged. MASH phase 3 development is distinct from obesity evidence.
Altimmune acquired Spitfire
Altimmune completed the Spitfire acquisition that brought the pemvidutide program into its portfolio.
Altimmune announced enrollment initiation in its global, randomized, placebo-controlled PERFORMA phase 3 MASH trial. The program targets histology and clinical outcomes; 52-week data are forecast for 2029. This is a historical development milestone, not a new efficacy result or an obesity approval.